These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16215959)

  • 61. Research on synthetic peptides of pharmaceutical interest at IDR.
    Bajusz S
    Pharmazie; 2001 Oct; 56 Suppl 1():S4-11. PubMed ID: 11686090
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production.
    Isidro-Llobet A; Kenworthy MN; Mukherjee S; Kopach ME; Wegner K; Gallou F; Smith AG; Roschangar F
    J Org Chem; 2019 Apr; 84(8):4615-4628. PubMed ID: 30900880
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bachem - Insights into Innovative and Sustainable Peptide Chemistry and Technology by the Leading Independent Manufacturer of TIDES.
    Jadhav S; Seufert W; Lechner C; Schönleber R
    Chimia (Aarau); 2021 Jun; 75(6):476-479. PubMed ID: 34233807
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Let us strengthen the relations between the clinical laboratory and manufacturer].
    YOSHIMURA H
    Rinsho Byori; 1962 Aug; 10():433-4. PubMed ID: 14002721
    [No Abstract]   [Full Text] [Related]  

  • 65. [Development of research on drugs in the pharmaceutical industry in the Hungarian People's Republic].
    KHORVAT D
    Med Prom SSSR; 1962 Dec; 12():50-2. PubMed ID: 14032405
    [No Abstract]   [Full Text] [Related]  

  • 66. Opportunities and challenges of developing peptide drugs in the pharmaceutical industry.
    Danho W; Swistok J; Khan W; Chu XJ; Cheung A; Fry D; Sun H; Kurylko G; Rumennik L; Cefalu J; Cefalu G; Nunn P
    Adv Exp Med Biol; 2009; 611():467-9. PubMed ID: 19400268
    [No Abstract]   [Full Text] [Related]  

  • 67. The ethical pharmaceutical manufacturer and the hospital pharmacy.
    MEES JL
    Hosp Manage; 1958 Jul; 86(1):86 passim. PubMed ID: 13548941
    [No Abstract]   [Full Text] [Related]  

  • 68. The physician looks at the pharmaceutical manufacturer and vice versa.
    BECKWITH ER
    Ariz Med; 1957 Dec; 14(12):758-63. PubMed ID: 13488747
    [No Abstract]   [Full Text] [Related]  

  • 69. As a pharmaceutical manufacturer sees it.
    BECKWITH ER
    Med Ann Dist Columbia; 1957 Nov; 26(11):611-5 passim. PubMed ID: 13476887
    [No Abstract]   [Full Text] [Related]  

  • 70. How a pharmaceutical manufacturer tests products for sterility.
    Slade JW
    Contam Control; 1966 Apr; 5(4):11 passim. PubMed ID: 4222253
    [No Abstract]   [Full Text] [Related]  

  • 71. [Contemporary problems of pharmaceutical research, production & utilization of drugs].
    SMAHEL O
    Cesk Zdrav; 1958 Aug; 6(8):423-9. PubMed ID: 13585492
    [No Abstract]   [Full Text] [Related]  

  • 72. [The state pharmaceutical laboratory; dedication of its new building].
    Sven Farm Tidskr; 1955 Apr; 59(11):286-8. PubMed ID: 14386329
    [No Abstract]   [Full Text] [Related]  

  • 73. An Approach to the Commercial Production of Highly Active Pharmaceutical Ingredients.
    Beyeler A; Wilhelm R; Brodbeck B
    Chimia (Aarau); 2016; 70(9):596-603. PubMed ID: 27646539
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Andhra University's pharmaceutical laboratories declared open.
    KAUR RA
    Calcutta Med J; 1951 Dec; 48(12):417-9. PubMed ID: 14905273
    [No Abstract]   [Full Text] [Related]  

  • 75. Abstracts of papers. Peptides as new leads in drug design. Tilburg (The Netherlands), 8 June 1990.
    Pharm Weekbl Sci; 1990 Jun; 12(3 Suppl E):E1-8. PubMed ID: 2367182
    [No Abstract]   [Full Text] [Related]  

  • 76. Peptides for Health Benefits 2019.
    Martínez-Villaluenga C; Hernández-Ledesma B
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32268522
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Future plans for investigation and production of drugs].
    SMAHEL O
    Cas Lek Cesk; 1958 Jun; 97(23-24):728-9. PubMed ID: 13561287
    [No Abstract]   [Full Text] [Related]  

  • 78. The two new ingredients.
    BOYER F
    J Indiana State Med Assoc; 1959 Nov; 52():2051; passim. PubMed ID: 13803572
    [No Abstract]   [Full Text] [Related]  

  • 79. The outlook for peptide drugs and the intricate relationship between the Active Pharmaceutical Ingredients manufacturer and their sponsors.
    de Chastonay J
    J Pept Sci; 2005 Nov; 11(11):754-5. PubMed ID: 16215959
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.